NRX Pharmaceuticals Inc (NRXP)
3.08
+0.09
(+3.01%)
USD |
NASDAQ |
Apr 23, 16:00
3.05
-0.03
(-0.97%)
After-Hours: 17:39
NRX Pharmaceuticals Free Cash Flow (Quarterly): -3.191M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -3.191M |
| September 30, 2023 | -4.566M |
| June 30, 2023 | -7.81M |
| March 31, 2023 | -6.093M |
| December 31, 2022 | -8.317M |
| September 30, 2022 | -6.271M |
| Date | Value |
|---|---|
| June 30, 2022 | -14.79M |
| March 31, 2022 | -10.38M |
| December 31, 2021 | -11.28M |
| September 30, 2021 | -12.02M |
| June 30, 2021 | -11.40M |
| March 31, 2021 | -3.015M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-14.79M
Minimum
Jun 2022
-3.015M
Maximum
Mar 2021
-8.261M
Average
-8.064M
Median
Free Cash Flow (Quarterly) Benchmarks
| Achieve Life Sciences Inc | -4.37M |
| Dare Bioscience Inc | -8.786M |
| Zevra Therapeutics Inc | -16.23M |
| Kodiak Sciences Inc | -59.72M |
| INmune Bio Inc | -3.401M |